Collectively, our results suggest that STC1 promotes tumorigenesis in breast cancer and that breast cancer patients with a high expression of STC1 are more resistant to treatment, potentially through promotion of the HR pathway, and therefore have worse survival. This evidence concerns the gene STC1 and breast carcinoma.